Patents by Inventor Christopher F. Claiborne

Christopher F. Claiborne has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20150183753
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: September 8, 2014
    Publication date: July 2, 2015
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • Aurora Kinase Inhibitors for Inhibiting Mitotic Progression
    Publication number: 20150166545
    Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Application
    Filed: October 15, 2014
    Publication date: June 18, 2015
    Inventors: Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20140303193
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: June 6, 2013
    Publication date: October 9, 2014
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney A. Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20130345242
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: June 6, 2013
    Publication date: December 26, 2013
    Applicant: MILLENNIUM PHARMACEUTICALS, INC.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney A. Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 8481550
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 24, 2011
    Date of Patent: July 9, 2013
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney A. Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
    Publication number: 20120178739
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: March 14, 2012
    Publication date: July 12, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF E1 ACTIVATING ENZYMES
    Publication number: 20120071482
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Application
    Filed: August 24, 2011
    Publication date: March 22, 2012
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • AURORA KINASE INHIBITORS FOR INHIBITING MITOTIC PROGRESSION
    Publication number: 20110312943
    Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Application
    Filed: August 25, 2011
    Publication date: December 22, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
  • AURORA KINASE INHIBITORS FOR INHIBITING MITOTIC PROGRESSION
    Publication number: 20110312942
    Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Application
    Filed: August 25, 2011
    Publication date: December 22, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
  • Aurora kinase inhibitors for inhibiting mitotic progression
    Patent number: 8026246
    Abstract: The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: September 27, 2011
    Assignee: Millennium Pharmaceuticials, Inc.
    Inventors: Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
  • Heteroaryl compounds useful as inhibitors of E1 activating enzymes
    Patent number: 8008307
    Abstract: This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: August 30, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Stephen Critchley, Courtney Cullis, Steven P. Langston, Hirotake Mizutani, Edward J. Olhava, Stephane Peluso, Irache Visiers, Stepan Vyskocil, Gabriel S. Weatherhead
  • Lactam compounds useful as protein kinase inhibitors
    Patent number: 7935694
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: May 3, 2011
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • LACTAM COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
    Publication number: 20110039820
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: October 13, 2010
    Publication date: February 17, 2011
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • Pyridobenzazepine compounds and methods for inhibiting mitotic progression
    Patent number: 7718648
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: August 6, 2007
    Date of Patent: May 18, 2010
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Todd B. Sells, Stephen G. Stroud
  • COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION
    Publication number: 20090299060
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Application
    Filed: May 27, 2009
    Publication date: December 3, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
  • 3-fluoro-piperidines as NMDA/NR2B antagonists
    Patent number: 7592360
    Abstract: Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, are effective as NMDA NR2B antagonists useful for treating conditions such as, for example, Parkinson's disease, Alzheimer's disease, migraine, epilepsy and pain.
    Type: Grant
    Filed: May 28, 2004
    Date of Patent: September 22, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Nigel J. Liverton, Christopher F. Claiborne, David A. Claremon, John A. McCauley
  • Compounds and methods for inhibiting mitotic progression
    Patent number: 7572784
    Abstract: This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.
    Type: Grant
    Filed: May 12, 2005
    Date of Patent: August 11, 2009
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher F. Claiborne, Lloyd J. Payne, Richard J. Boyce, Todd B. Sells, Stephen G. Stroud, Stuart Travers, Tricia J. Vos, Gabriel S. Weatherhead
  • Lactam compounds useful as protein kinase inhibitors
    Publication number: 20090105213
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Application
    Filed: September 4, 2008
    Publication date: April 23, 2009
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • Lactam compounds useful as protein kinase inhibitors
    Patent number: 7459448
    Abstract: The present invention provides novel compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.
    Type: Grant
    Filed: October 3, 2005
    Date of Patent: December 2, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Christopher Blackburn, Christopher F. Claiborne, Courtney A. Cullis, Natalie A. Dales, Michael Patane, Matthew Stirling, Omar Stradella, Gabriel S. Weatherhead
  • Melanocortin-4 receptor binding compounds and methods of use thereof
    Publication number: 20080269217
    Abstract: Provided are MC4-R binding compounds of the formula XVII: wherein L2 is a linker group, and P1, P2, P3, P4, Z1, Z2, Z3, Z4, Z5, t, s, and R are as described in the specification. Methods of using the compounds to treat MC4-R associated disorders, such as disorders associated with weight loss, are also provided.
    Type: Application
    Filed: May 1, 2008
    Publication date: October 30, 2008
    Applicant: Ore Pharmaceuticals, Inc.
    Inventors: Tricia J. Vos, Michael E. Solomon, Christopher F. Claiborne, Martin P. Maguire, Mingshi Dai, Michael Patane, Thoma H. Marsilje